Dyania Health, an AI-powered healthcare data company, today announced the close of its $10 million Series A funding round led by HealthX Ventures with Tech Square Ventures and Cleveland Clinic Ventures, along with significant participation from existing investors.
Dyania’s Series A is driven by the growing demand for innovative solutions that address inefficiencies in healthcare data management and clinical research, positioning Dyania Health as a leader in AI-powered healthcare technologies.
Dyania’s platform is initially being used at large healthcare systems to unlock enterprise-wide clinical trial pre-screening, run automated chart review for observational studies, and automate complex registry reporting, dramatically reducing manual workloads and ensuring more accurate and timely patient care.
Dyania’s founding mission in 2020 was to develop medically specialized and proprietary AI that empowers clinicians to deliver optimal care, precisely when patients need it, by automating manual chart review, one of the most inefficient and time-consuming processes in modern healthcare.
Eirini Schlosser, CEO & Founder, started with the vision to build a team of full-time physicians who would work alongside applied AI researchers, bridging mathematical acumen with medical expertise. Collectively, they spent the COVID19 pandemic working hand-in-hand to respectively annotate mass data sets and ultimately utilize those annotated EMRs to train their LLM and build their proprietary Synapsis AI platform, Dyania Health’s flagship product. During its development phase, Dyania Health took a first-mover decision to acquire GPU for computing resources and then focused on continuous innovation and training its models, which now consistently outperform human experts in medical chart review.
Dyania Health has formed strategic partnerships and commercial relationships with several prominent healthcare systems and life sciences firms. These have included various academic medical centers with significant clinical research operations, high volumes of diverse patient populations, and computational infrastructure and resources. Notably, one of the first movers has been the Cleveland Clinic with an enterprise-wide roll-out now underway after a year of working with Dyania Health in the cancer and cardiovascular disease areas.
“Artificial intelligence has the capability to enhance patient care and increase the speed of medical research. This project combines both of these elements,” said Rohit Chandra, PhD, Cleveland Clinic’s Chief Digital Officer. “Through our work together with Dyania and the clinical leadership of Cleveland Clinic’s Heart, Vascular and Thoracic Institute and Cancer Institute, we have seen early success with the technology in streamlining and accelerating the clinical trial recruitment process. The system’s medically trained large language model pre-screens electronic medical records to identify patients who meet clinical eligibility criteria for cardiovascular and oncology studies, alleviating traditional bottlenecks in enrollment and potentially giving more patients access to clinical trials.”
“Our vision is to revolutionize how healthcare systems and life sciences companies interact with the wealth of unstructured medical data trapped in clinical records,” said Eirini Schlosser, CEO and Founder of Dyania Health. “This funding will allow us to expand our AI capabilities and continue partnering with more leading organizations to drive improved outcomes in clinical research and patient care.”
The Synapsis AI Platform leverages its proprietary LLM along with advanced data engineering to deduce critical, actionable insights from both large volumes of unstructured medical records —such as physician notes, pathology reports, and imaging notes— and structured data such as codified information or numerical lab results. Importantly, patient EMR data remains within the health system’s firewall, with AI processing done locally, ensuring that data never leaves the healthcare system’s computing environment. This maintains the integrity of patient data privacy and exceeds HIPAA and GDPR requirements.
What previously took a human over 30 minutes to read manually, Synapsis AI can perform in less than half a second, transforming the speed and scale at which clinical decisions can be made and revolutionizing the availability of concise information at the physician’s fingertips. Scale this up with more computing power, and the math becomes clear: what was not humanly possible before, is now with Synapsis AI.
Dyania Health’s leadership team includes experts from industry-leading organizations such as Amazon Alexa AI, Bloomberg AI, Flatiron Health, and NYU Langone, among others, bringing together deep AI research, clinical, and engineering acumen.
With the completion of this Series A funding, Dyania Health plans to expand its team, enhance its product capabilities, and scale its operations to meet growing demand from healthcare systems and biopharmaceutical companies.